Trial Profile
Evaluation of the Efficacy of Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2023
Price :
$35
*
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary)
- Indications Headache
- Focus Therapeutic Use
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Apr 2012 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 23 Aug 2010 Additional lead trial investigator (Duren M Ready) identified as reported by ClinicalTrials.gov.